Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.


Recent statements from the FDA in support of accelerating the approval pathway for ultra-rare disorders include "plausible mechanisms" rather than traditional randomized controlled trials, which are often impractical or infeasible for ultra rare disease patient populations.
This IQVIA RWS response discusses the importance of acknowledging the existing approved new products that have included real world evidence (RWE) for rare diseases, and explains how successful use cases of real world data (RWD) and RWE will continue to support life sciences and patient advocacy partners in advocating for patients and the accelerated approval of more treatments.
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
Incorporate the patient voice in real world studies to improve outcomes for patients and caregivers